Antiphospholipid Antibodies in a General Obstetric Population: Clinical Impact on Pregnancy Outcome and Relationship with the M2 Haplotype in the Annexin A5 (ANXA5) Gene

Michela Villani, Donatella Colaizzo, Pasquale Martinelli, Filomena Cappucci, Lucia Fischetti, Giuseppe M. Maruotti, Mariano Intrieri, Luigi Greco, Elena Chinni, Giovanni L. Tiscia, Maurizio Margaglione, Elvira Grandone

Research output: Contribution to journalArticle

Abstract

Antiphospholipid (aPL) antibodies are recognised risk factors for adverse obstetric outcomes. Recently, carriers of the M2 haplotype in the Annexin A5 gene have been shown to have a higher susceptibility to develop aPL antibodies. In a general obstetric population, we prospectively evaluated the possible relationship between: (1) aPL antibodies and M2 haplotype; and (2) aPL antibodies and/or M2 haplotype and obstetric outcomes. From a cohort of 3,097 consecutive pregnant women, 1,286 samples were analysed for the presence of both anti-cardiolipin and anti-human 2-glycoprotein I antibodies; samples with available DNA (n = 606) were also investigated for the M2 haplotype. Overall, 41/1,286 (3.2%) women showed the presence of aPL antibodies. Among them, 2 (4.8%) experienced a pregnancy loss and 38 (92.7%) gave birth to live-born babies (p -value = non-significant vs. those without aPL antibodies). M2 haplotype was identified in 140 (23.1%) out of 606 women with DNA available: 3/140 (2.1%) M2 carriers and 17/466 (3.6%) non-carriers tested positive for aPL antibodies, respectively (p -value = non-significant). In total, 15/150 (10%) M2 and/or aPL antibody carriers, and 38/445 (8.5%) non-aPL antibody and/or M2 carriers suffered from obstetric complications, respectively (p -value = non-significant). No relationship between aPL antibodies and M2 haplotype was found. Furthermore, neither aPL antibodies nor the M2 haplotype is associated with obstetric complications.

Original languageEnglish
Pages (from-to)203-207
Number of pages5
JournalHamostaseologie
Volume39
Issue number2
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Annexins
Antiphospholipid Antibodies
Pregnancy Outcome
Haplotypes
Obstetrics
Population
Genes
Cardiolipins
Antibodies
DNA
Live Birth
Pregnant Women
Glycoproteins

Keywords

  • annexins
  • antiphospholipid antibodies
  • pregnancy

ASJC Scopus subject areas

  • Hematology

Cite this

Antiphospholipid Antibodies in a General Obstetric Population : Clinical Impact on Pregnancy Outcome and Relationship with the M2 Haplotype in the Annexin A5 (ANXA5) Gene. / Villani, Michela; Colaizzo, Donatella; Martinelli, Pasquale; Cappucci, Filomena; Fischetti, Lucia; Maruotti, Giuseppe M.; Intrieri, Mariano; Greco, Luigi; Chinni, Elena; Tiscia, Giovanni L.; Margaglione, Maurizio; Grandone, Elvira.

In: Hamostaseologie, Vol. 39, No. 2, 01.01.2019, p. 203-207.

Research output: Contribution to journalArticle

Villani, Michela ; Colaizzo, Donatella ; Martinelli, Pasquale ; Cappucci, Filomena ; Fischetti, Lucia ; Maruotti, Giuseppe M. ; Intrieri, Mariano ; Greco, Luigi ; Chinni, Elena ; Tiscia, Giovanni L. ; Margaglione, Maurizio ; Grandone, Elvira. / Antiphospholipid Antibodies in a General Obstetric Population : Clinical Impact on Pregnancy Outcome and Relationship with the M2 Haplotype in the Annexin A5 (ANXA5) Gene. In: Hamostaseologie. 2019 ; Vol. 39, No. 2. pp. 203-207.
@article{38833a3e47194b58b1e8ab9e76cbadc5,
title = "Antiphospholipid Antibodies in a General Obstetric Population: Clinical Impact on Pregnancy Outcome and Relationship with the M2 Haplotype in the Annexin A5 (ANXA5) Gene",
abstract = "Antiphospholipid (aPL) antibodies are recognised risk factors for adverse obstetric outcomes. Recently, carriers of the M2 haplotype in the Annexin A5 gene have been shown to have a higher susceptibility to develop aPL antibodies. In a general obstetric population, we prospectively evaluated the possible relationship between: (1) aPL antibodies and M2 haplotype; and (2) aPL antibodies and/or M2 haplotype and obstetric outcomes. From a cohort of 3,097 consecutive pregnant women, 1,286 samples were analysed for the presence of both anti-cardiolipin and anti-human 2-glycoprotein I antibodies; samples with available DNA (n = 606) were also investigated for the M2 haplotype. Overall, 41/1,286 (3.2{\%}) women showed the presence of aPL antibodies. Among them, 2 (4.8{\%}) experienced a pregnancy loss and 38 (92.7{\%}) gave birth to live-born babies (p -value = non-significant vs. those without aPL antibodies). M2 haplotype was identified in 140 (23.1{\%}) out of 606 women with DNA available: 3/140 (2.1{\%}) M2 carriers and 17/466 (3.6{\%}) non-carriers tested positive for aPL antibodies, respectively (p -value = non-significant). In total, 15/150 (10{\%}) M2 and/or aPL antibody carriers, and 38/445 (8.5{\%}) non-aPL antibody and/or M2 carriers suffered from obstetric complications, respectively (p -value = non-significant). No relationship between aPL antibodies and M2 haplotype was found. Furthermore, neither aPL antibodies nor the M2 haplotype is associated with obstetric complications.",
keywords = "annexins, antiphospholipid antibodies, pregnancy",
author = "Michela Villani and Donatella Colaizzo and Pasquale Martinelli and Filomena Cappucci and Lucia Fischetti and Maruotti, {Giuseppe M.} and Mariano Intrieri and Luigi Greco and Elena Chinni and Tiscia, {Giovanni L.} and Maurizio Margaglione and Elvira Grandone",
year = "2019",
month = "1",
day = "1",
doi = "10.1055/s-0038-1673414",
language = "English",
volume = "39",
pages = "203--207",
journal = "Hamostaseologie",
issn = "0720-9355",
publisher = "Schattauer GmbH",
number = "2",

}

TY - JOUR

T1 - Antiphospholipid Antibodies in a General Obstetric Population

T2 - Clinical Impact on Pregnancy Outcome and Relationship with the M2 Haplotype in the Annexin A5 (ANXA5) Gene

AU - Villani, Michela

AU - Colaizzo, Donatella

AU - Martinelli, Pasquale

AU - Cappucci, Filomena

AU - Fischetti, Lucia

AU - Maruotti, Giuseppe M.

AU - Intrieri, Mariano

AU - Greco, Luigi

AU - Chinni, Elena

AU - Tiscia, Giovanni L.

AU - Margaglione, Maurizio

AU - Grandone, Elvira

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Antiphospholipid (aPL) antibodies are recognised risk factors for adverse obstetric outcomes. Recently, carriers of the M2 haplotype in the Annexin A5 gene have been shown to have a higher susceptibility to develop aPL antibodies. In a general obstetric population, we prospectively evaluated the possible relationship between: (1) aPL antibodies and M2 haplotype; and (2) aPL antibodies and/or M2 haplotype and obstetric outcomes. From a cohort of 3,097 consecutive pregnant women, 1,286 samples were analysed for the presence of both anti-cardiolipin and anti-human 2-glycoprotein I antibodies; samples with available DNA (n = 606) were also investigated for the M2 haplotype. Overall, 41/1,286 (3.2%) women showed the presence of aPL antibodies. Among them, 2 (4.8%) experienced a pregnancy loss and 38 (92.7%) gave birth to live-born babies (p -value = non-significant vs. those without aPL antibodies). M2 haplotype was identified in 140 (23.1%) out of 606 women with DNA available: 3/140 (2.1%) M2 carriers and 17/466 (3.6%) non-carriers tested positive for aPL antibodies, respectively (p -value = non-significant). In total, 15/150 (10%) M2 and/or aPL antibody carriers, and 38/445 (8.5%) non-aPL antibody and/or M2 carriers suffered from obstetric complications, respectively (p -value = non-significant). No relationship between aPL antibodies and M2 haplotype was found. Furthermore, neither aPL antibodies nor the M2 haplotype is associated with obstetric complications.

AB - Antiphospholipid (aPL) antibodies are recognised risk factors for adverse obstetric outcomes. Recently, carriers of the M2 haplotype in the Annexin A5 gene have been shown to have a higher susceptibility to develop aPL antibodies. In a general obstetric population, we prospectively evaluated the possible relationship between: (1) aPL antibodies and M2 haplotype; and (2) aPL antibodies and/or M2 haplotype and obstetric outcomes. From a cohort of 3,097 consecutive pregnant women, 1,286 samples were analysed for the presence of both anti-cardiolipin and anti-human 2-glycoprotein I antibodies; samples with available DNA (n = 606) were also investigated for the M2 haplotype. Overall, 41/1,286 (3.2%) women showed the presence of aPL antibodies. Among them, 2 (4.8%) experienced a pregnancy loss and 38 (92.7%) gave birth to live-born babies (p -value = non-significant vs. those without aPL antibodies). M2 haplotype was identified in 140 (23.1%) out of 606 women with DNA available: 3/140 (2.1%) M2 carriers and 17/466 (3.6%) non-carriers tested positive for aPL antibodies, respectively (p -value = non-significant). In total, 15/150 (10%) M2 and/or aPL antibody carriers, and 38/445 (8.5%) non-aPL antibody and/or M2 carriers suffered from obstetric complications, respectively (p -value = non-significant). No relationship between aPL antibodies and M2 haplotype was found. Furthermore, neither aPL antibodies nor the M2 haplotype is associated with obstetric complications.

KW - annexins

KW - antiphospholipid antibodies

KW - pregnancy

UR - http://www.scopus.com/inward/record.url?scp=85070222557&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070222557&partnerID=8YFLogxK

U2 - 10.1055/s-0038-1673414

DO - 10.1055/s-0038-1673414

M3 - Article

AN - SCOPUS:85070222557

VL - 39

SP - 203

EP - 207

JO - Hamostaseologie

JF - Hamostaseologie

SN - 0720-9355

IS - 2

ER -